Transition of patients from chronic kidney disease to end-stage renal disease: Better practices for better outcomes

Disease Management

Volumn 9, Issue 6, 2006, Pages 311-315

  Amedia Jr , Chester A ^a   Perazella, Mark A ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; IRON; NONSTEROID ANTIINFLAMMATORY AGENT;

ANEMIA; ARTERIOVENOUS FISTULA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG SURVEILLANCE PROGRAM; EARLY DIAGNOSIS; ECONOMIC EVALUATION; EMERGENCY TREATMENT; FRACTURE; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; KIDNEY GRAFT; NEPHROLOGIST; PATIENT EDUCATION; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RENAL OSTEODYSTROPHY; REVIEW; VACCINATION; VASCULAR ACCESS;

ANEMIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES;

EID: 33845436283     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2006.9.311     Document Type: Review

References (26)

1. U.S. Renal Data System (USRDS). 2005 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
2. Martinez-Ramirez HR, Jalomo-Martinez B, Cortes-Sanabria L, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis 2006;47:78-87.
3. Nwankwo E, Bello AK, El Nahas AM. Chronic kidney disease: stemming the global tide. Am J Kidney Dis 2005;45:201-208.
4. Mix TC, St. Peter WL, Ebben J, et al. Hospitalization during advancing chronic kidney disease. Am J Kidney Dis 2003;42:972-981.
5. Collins AJ, Li S, Gilbertson DT, Liu J, Chen S-C, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 2003;87:S24-S31.
6. Thomas MC, Rosengard-Barlund M, Mills V, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006;29:317-322.
7. Levin A, Lewis M, Mortiboy P, et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis 1997;29:533-540.
8. Schmidt RJ, Domico JR, Sorkin MI, Hobbs G. Early referral and its impact on emergent first dialyses, health care costs, and outcome. Am J Kidney Dis 1998;32:278-283.
9. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003;14:1863-1870.
10. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. K/DOQI clinical practice guidelines for vascular access, update 2000. Am J Kidney Dis 2001;37(suppl 1).
11. Fistula First National Vascular Access Improvement Initiative. Fistula First outcomes dashboard v1.3. 2006:5-6.
12. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17:2094-2105.
13. Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int 2005;95:S8-S12.
14. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;73:S14-S19.
15. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
16. Brown AJ, Coyne DW. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. Treat Endocrinol 2002;1:313-327.
17. Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int 2005;96:S2-S6.
18. Braithwaite RS, Col NF, Wang JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003;51:364-370.
19. U.S. Renal Data System. 2005 USRDS annual data report reference tables: reference sections. Minneapolis, MN: U.S. Renal Data System, 2005.
20. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. Kidney Int 2005;67:1483-1488.
21. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001;161:1207-1216.
22. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999;10:1793-1800.
23. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134.
24. Fink J, Blahut SA, Reddy M, Light PD. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-355.
25. McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis 1997;29:368-375.
26. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-1187.